To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis

Last updated: December 13, 2013
Sponsor: UCB Pharma
Overall Status: Completed

Phase

3

Condition

Allergy

Common Cold

Nasal Obstruction

Treatment

N/A

Clinical Study ID

NCT00525278
A00348
  • Ages 18-60
  • All Genders

Study Summary

To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female, 18 to 60 years old, inclusive

  • two-year history of allergic rhinitis due to tree, grass or weed pollen

  • sufficient histamine-dependent symptoms of rhinitis during the selection week (T5SS ≥

Exclusion

Exclusion Criteria:

  • An ear, nose or throat (ENT) infection

  • asthma requiring daily drug therapy other than ß2 inhaled agonists taken prn

  • atopic dermatitis or urticaria requiring an antihistamine or corticosteroid treatment

  • an associated ENT disease

  • use of decongestants

  • nasal or ocular topical treatment

Study Design

Total Participants: 67
Study Start date:
August 01, 2003
Estimated Completion Date:
October 31, 2003